ly 300164 has been researched along with Epilepsy in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 5 (83.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chimirri, A; De Sarro, A; De Sarro, G; Ferreri, G; Gitto, R; Orlando, V; Quartarone, S; Russo, E | 1 |
Aujla, PK; Fishman, R; Jensen, FE; Rakhade, SN; Sucher, NJ; Zhou, C | 1 |
Banczerowski-Pelyhe, I; Gulyás-Kovács, A; Takács, J; Tarnawa, I; Világi, I | 1 |
Jewell, H; Langan, YM; Lucas, R; Patsalos, PN; Sander, JW; Schaefer, H; Toublanc, N | 1 |
Bell, C; Howes, JF | 1 |
Gacsályi, I; Gigler, G; Gyertyán, I; Lévay, G; Szabados, T | 1 |
1 review(s) available for ly 300164 and Epilepsy
Article | Year |
---|---|
Talampanel.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Brain; Clinical Trials as Topic; Epilepsy; Humans | 2007 |
1 trial(s) available for ly 300164 and Epilepsy
Article | Year |
---|---|
Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Benzodiazepines; Biological Availability; Chronic Disease; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Epilepsy; Female; Humans; Male; Middle Aged | 2003 |
4 other study(ies) available for ly 300164 and Epilepsy
Article | Year |
---|---|
Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Benzodiazepines; Disease Models, Animal; Epilepsy; Excitatory Amino Acid Agonists; In Vitro Techniques; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred DBA; Neurons; Olfactory Pathways; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Structure-Activity Relationship; Triazoles | 2003 |
Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures.
Topics: Animals; Animals, Newborn; Anticonvulsants; Benzodiazepines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP-Dependent Protein Kinases; Disease Susceptibility; Enzyme Activation; Epilepsy; Excitatory Postsynaptic Potentials; Fructose; Hypoxia; Male; Phosphorylation; Protein Kinase C; Quinoxalines; Rats; Rats, Long-Evans; Receptors, AMPA; Synapses; Topiramate | 2008 |
Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Anti-Anxiety Agents; Asphyxia Neonatorum; Behavior, Animal; Benzodiazepines; Cell Death; Epilepsy; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Hypoxia-Ischemia, Brain; Infant, Newborn; Male; Movement Disorders; Neostriatum; Neuroprotective Agents; Neurotoxins; Rats; Receptors, AMPA; Synaptic Transmission | 2002 |
Duration of action of GYKI 52466 and its analogues in antiepileptic, anti-ischaemic and muscle relaxant tests.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Mice; Muscle Relaxants, Central | 1999 |